Abstract Guidelines

Abstract Submission Deadline: May 18, 2021

Late-Breaking Submission will be from May 24 - June 4, 2021

***Please note,  if an author wishes to make changes or withdraw their abstract, they must contact the HiD team no later than August 14, 2020. HiD cannot guarantee that any change or withdraw requests submitted after this date will be accommodated. All requests should be submitted via e-mail to info@tmioa.com

       Editor-in-Chief: Daniel Mark, MD, MPH

  • Accepted Abstracts will have a poster presentation at the meeting

  • Top Abstracts will be selected for oral presentation at the meeting

  • In some cases, the committee may consider Late-Breaking Abstracts for oral presentation

  • Top 4 Abstracts will receive awards and cash prizes

View Sample Abstract Submission

Abstract Submission Topics

Abstracts should address state-of-the-art clinical research aspects of diabetes and the heart. (As an example, obesity by itself will NOT qualify, but obesity, as it relates to diabetes and/or cardiovascular disease, will qualify).
 
Topics include: diabetes, hypoglycemia, prediabetes, and/or cardiometabolic syndrome, retinopathy, obesity, neuropathy, dyslipidemia, triglycerides, cholesterol, hypertension, congestive heart failure (CHF), atherosclerosis, cardiovascular disease, arrhythmia, kidney/renal disease, cardiorenal syndrome, thrombosis, coagulation abnormalities, therapeutics, clinical trials, cardiovascular outcome trials, epidemiology, fatty liver, inflammation, guidelines on practice, technology, peripheral vascular disease, and related conditions
 
Although the posters are not designed for basic science, abstracts that consider unknown MOA (mode of action) of medications or pathophysiology of related medical conditions may be accepted.

Abstract Visual Poster Presentations

Abstracts may be submitted for a virtual poster presentation. If selected for poster presentation, the author or presenter is required to register for the conference.

Abstract Oral Presentations

Four of the highest-ranking abstracts will be selected for the Abstract Oral Presentation Session - Date & Time: TBA. In some cases, the committee may consider Late-Breaking Abstracts for oral presentation. The authors of the winning abstracts will present their research findings in a 10-minute presentation, followed by a 5 minute period of Q&A. If selected, an author is required to register to the meeting and to be prepared with a PowerPoint presentation. Oral presenters who have an interest or involvement in selling a technology, program, product, and/or service to healthcare professionals must submit an official disclosure document in order to be considered for and to present their work at the abstract oral session.

Top Abstract Awards

Awards will be given to the highest-ranking abstracts. The award levels are Gold, Silver, Bronze, and honorable mention. 

In addition:

  • Scientific materials presented at the 4th Annual Heart in Diabetes (2020) must not have been published or presented prior to August 21, 2020, other than in abstract form.

  • All abstracts must be submitted electronically and should be no more than 250 words (Titles, author(s) names, and affiliations are not included in the word count).

  • Graphs or figures submitted must be in TIFF or JPG format.

  • All materials must arrive on or before the abstract deadline noted above.

  • Notification for acceptance will be e-mailed as soon as the committee accepts the abstract.

  • Authorship on multiple abstracts is permitted.

  • All submitted content will be graded by the 2020 Heart in Diabetes Scientific Abstract Committee.

  • Abstracts will be published in the October 2020 issue of the American Heart Journal.



 
american-heart-journal-640x400.jpg
Daniel Mark Editor in Chief.jpg

18372 Clark St.

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter